$SPRB
SPRUCE BIOSCIENCES, INC.

2023 Q3 Form 10-Q Financial Statement

#000095017023042439 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $3.100M $2.200M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.240M $3.011M $2.822M
YoY Change 17.14% 6.7% 8.75%
% of Gross Profit
Research & Development $13.49M $13.13M $9.060M
YoY Change 53.5% 44.88% -0.65%
% of Gross Profit
Depreciation & Amortization $10.00K $18.00K $9.000K
YoY Change -56.52% 100.0% 80.0%
% of Gross Profit
Operating Expenses $16.73M $16.14M $11.88M
YoY Change 44.77% 35.81% 1.43%
Operating Profit -$13.66M -$13.97M -$11.88M
YoY Change 18.18% 17.59% 1.43%
Interest Expense $119.0K $127.0K $94.00K
YoY Change 8.18% 35.11% 17.5%
% of Operating Profit
Other Income/Expense, Net $1.420M $1.275M $104.0K
YoY Change 433.83% 1125.96% 420.0%
Pretax Income -$12.35M -$12.82M -$11.87M
YoY Change 8.32% 8.02% 0.83%
Income Tax
% Of Pretax Income
Net Earnings -$12.35M -$12.82M -$11.87M
YoY Change 8.36% 8.02% 0.83%
Net Earnings / Revenue -398.52% -582.91%
Basic Earnings Per Share -$0.30 -$0.32 -$0.51
Diluted Earnings Per Share -$0.30 -$0.32 -$505.3K
COMMON SHARES
Basic Shares Outstanding 40.71M 39.75M 23.49M
Diluted Shares Outstanding 40.71M 40.55M 23.49M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.0M $120.5M $93.30M
YoY Change 19.47% 29.18% -14.58%
Cash & Equivalents $98.80M $97.48M $47.21M
Short-Term Investments $9.200M $23.04M $46.09M
Other Short-Term Assets $419.0K $206.0K $390.0K
YoY Change -84.96% -47.18% -81.83%
Inventory
Prepaid Expenses $2.687M $3.400M $2.821M
Receivables
Other Receivables
Total Short-Term Assets $111.1M $124.1M $96.51M
YoY Change 19.26% 28.62% -13.35%
LONG-TERM ASSETS
Property, Plant & Equipment $1.200M $1.297M $127.0K
YoY Change -2.36% 921.26% -92.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.805M
YoY Change -80.5%
Other Assets $607.0K $536.0K $674.0K
YoY Change -9.0% -20.47% 0.15%
Total Long-Term Assets $1.847M $1.833M $8.009M
YoY Change -12.55% -77.11% -75.03%
TOTAL ASSETS
Total Short-Term Assets $111.1M $124.1M $96.51M
Total Long-Term Assets $1.847M $1.833M $8.009M
Total Assets $113.0M $126.0M $104.5M
YoY Change 18.56% 20.52% -27.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.152M $945.0K $1.445M
YoY Change 44.52% -34.6% 29.83%
Accrued Expenses $11.60M $12.11M $7.846M
YoY Change 34.82% 54.31% 33.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.622M $1.622M $811.0K
YoY Change 33.39% 100.0%
Total Short-Term Liabilities $24.19M $22.73M $10.10M
YoY Change 101.55% 125.04% 44.73%
LONG-TERM LIABILITIES
Long-Term Debt $2.113M $2.507M $4.077M
YoY Change -42.66% -38.51% -16.02%
Other Long-Term Liabilities $220.0K $202.0K $117.0K
YoY Change 58.27% 72.65% -92.24%
Total Long-Term Liabilities $2.333M $2.709M $4.194M
YoY Change -38.99% -35.41% -13.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.19M $22.73M $10.10M
Total Long-Term Liabilities $2.333M $2.709M $4.194M
Total Liabilities $27.60M $29.40M $15.39M
YoY Change 64.08% 90.99% 15.38%
SHAREHOLDERS EQUITY
Retained Earnings -$187.3M -$174.9M -$126.8M
YoY Change 35.53% 37.93% 53.7%
Common Stock $272.7M $271.5M $216.7M
YoY Change 25.35% 25.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.38M $96.56M $89.12M
YoY Change
Total Liabilities & Shareholders Equity $113.0M $126.0M $104.5M
YoY Change 18.56% 20.52% -27.14%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$12.35M -$12.82M -$11.87M
YoY Change 8.36% 8.02% 0.83%
Depreciation, Depletion And Amortization $10.00K $18.00K $9.000K
YoY Change -56.52% 100.0% 80.0%
Cash From Operating Activities -$12.27M $1.993M -$9.541M
YoY Change 43.04% -120.89% -1.55%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00 -$6.000K
YoY Change -600.0% -100.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities $14.00M $22.00M $33.51M
YoY Change -182.88% -34.35% -155.09%
Cash From Investing Activities $14.00M $22.00M $33.51M
YoY Change -182.87% -34.34% -155.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -410.0K -432.0K -99.00K
YoY Change 355.56% 336.36% -155.31%
NET CHANGE
Cash From Operating Activities -12.27M 1.993M -9.541M
Cash From Investing Activities 14.00M 22.00M 33.51M
Cash From Financing Activities -410.0K -432.0K -99.00K
Net Change In Cash 1.320M 23.56M 23.87M
YoY Change -105.16% -1.28% -133.93%
FREE CASH FLOW
Cash From Operating Activities -$12.27M $1.993M -$9.541M
Capital Expenditures $10.00K $0.00 -$6.000K
Free Cash Flow -$12.28M $1.993M -$9.535M
YoY Change 43.19% -120.9% -1.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001683553
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39594
dei Entity Registrant Name
EntityRegistrantName
Spruce Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2154263
dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 740
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-82000
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
655-4168
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SPRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40710692
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97482000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24487000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
23041000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
54590000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3400000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3320000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
206000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1211000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
124129000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
83608000
CY2023Q2 sprb Lease Right Of Use Asset
LeaseRightOfUseAsset
1297000
CY2022Q4 sprb Lease Right Of Use Asset
LeaseRightOfUseAsset
1400000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
536000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
640000
CY2023Q2 us-gaap Assets
Assets
125962000
CY2022Q4 us-gaap Assets
Assets
85648000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
945000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1426000
CY2023Q2 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12107000
CY2022Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9399000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8060000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22734000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12447000
CY2023Q2 sprb Lease Liability Noncurrent
LeaseLiabilityNoncurrent
1147000
CY2022Q4 sprb Lease Liability Noncurrent
LeaseLiabilityNoncurrent
1261000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2507000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3293000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2811000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
202000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
161000
CY2023Q2 us-gaap Liabilities
Liabilities
29401000
CY2022Q4 us-gaap Liabilities
Liabilities
17162000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40710692
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40710692
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23601004
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23601004
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
271540000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
218354000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-55000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-558000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174928000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149313000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
96561000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
68486000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125962000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85648000
CY2023Q2 us-gaap Revenues
Revenues
2165000
CY2022Q2 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
4129000
us-gaap Revenues
Revenues
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13126000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9060000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24838000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17568000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3011000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2822000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6462000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6048000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
16137000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
11882000
us-gaap Operating Expenses
OperatingExpenses
31300000
us-gaap Operating Expenses
OperatingExpenses
23616000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13972000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11882000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27171000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23616000
CY2023Q2 us-gaap Interest Expense
InterestExpense
127000
CY2022Q2 us-gaap Interest Expense
InterestExpense
94000
us-gaap Interest Expense
InterestExpense
258000
us-gaap Interest Expense
InterestExpense
181000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1275000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
104000
us-gaap Interest And Other Income
InterestAndOtherIncome
1814000
us-gaap Interest And Other Income
InterestAndOtherIncome
162000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12824000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
us-gaap Net Income Loss
NetIncomeLoss
-25615000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
133000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
503000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12691000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12024000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25112000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24296000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40547925
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40547925
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23493613
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23493613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36247931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36247931
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23492960
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23492960
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
107997000
CY2023Q2 sprb Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
8000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
99000
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-71000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1219000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
133000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12824000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
96561000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
68486000
sprb Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
8000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
99000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-94000
sprb Common Stock And Warrant Net Offering Costs
CommonStockAndWarrantNetOfferingCosts
2721000
sprb Stock Issued During Period Value Of Common Stock And Warrants
StockIssuedDuringPeriodValueOfCommonStockAndWarrants
50895000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2279000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
503000
us-gaap Net Income Loss
NetIncomeLoss
-25615000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
96561000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
100243000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
905000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89121000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111371000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2046000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89121000
us-gaap Profit Loss
ProfitLoss
-25615000
us-gaap Profit Loss
ProfitLoss
-23635000
us-gaap Share Based Compensation
ShareBasedCompensation
2279000
us-gaap Share Based Compensation
ShareBasedCompensation
2046000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
37000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
27000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
432000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-108000
sprb Non Cash Lease Expense
NonCashLeaseExpense
114000
sprb Non Cash Lease Expense
NonCashLeaseExpense
166000
sprb Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
2000
sprb Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-709000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
285000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-145000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-481000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1378000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2656000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1688000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10871000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-131000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9797000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21367000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11881000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12978000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
44365000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
39000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32484000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26016000
sprb Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
53616000
sprb Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
99000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
38000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2721000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
227000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
811000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50097000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-187000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
72784000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4462000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24732000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42964000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97516000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47426000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97482000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47210000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
34000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
216000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97516000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47426000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
120500000
us-gaap Net Income Loss
NetIncomeLoss
-25600000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
9800000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174900000
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses as well as related disclosure of contingent assets and liabilities. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, accrued research and development expenses, revenue recognition, stock-based compensation, and uncertain tax positions. The Company bases its estimates on its historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
118136000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
62000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
118081000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
77644000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
559000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
77086000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
16743000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
77000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
34911000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
482000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
51654000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
559000
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
CY2023Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0
sprb Weighted Average Remaining Contractual Term Maturities Available For Sale
WeightedAverageRemainingContractualTermMaturitiesAvailableForSale
P3M
sprb Cash Equivalents And Short Term Investments Due Term
CashEquivalentsAndShortTermInvestmentsDueTerm
P1Y
CY2023Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4200000
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4900000
CY2023Q2 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
9853000
CY2022Q4 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
7449000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1678000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1286000
CY2023Q2 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
340000
CY2022Q4 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
525000
CY2023Q2 sprb Lease Liability Current
LeaseLiabilityCurrent
236000
CY2022Q4 sprb Lease Liability Current
LeaseLiabilityCurrent
139000
CY2023Q2 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12107000
CY2022Q4 sprb Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9399000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
982000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1856000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1711000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
136000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
4685000
CY2023Q2 sprb Debt Interest
DebtInterest
496000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4189000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
60000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1622000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2507000
CY2023Q2 us-gaap Revenues
Revenues
2200000
us-gaap Revenues
Revenues
4100000
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
10900000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8100000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21566236
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7704202
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1219000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
905000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2279000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2046000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12824000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
us-gaap Net Income Loss
NetIncomeLoss
-25615000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40547925
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40547925
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23493613
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23493613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36247931
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36247931
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23492960
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23492960
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19958430
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4519198

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-042439-index-headers.html Edgar Link pending
0000950170-23-042439-index.html Edgar Link pending
0000950170-23-042439.txt Edgar Link pending
0000950170-23-042439-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sprb-20230630.htm Edgar Link pending
sprb-20230630.xsd Edgar Link pending
sprb-ex31_1.htm Edgar Link pending
sprb-ex31_2.htm Edgar Link pending
sprb-ex32_1.htm Edgar Link pending
sprb-ex32_2.htm Edgar Link pending
sprb-20230630_cal.xml Edgar Link unprocessable
sprb-20230630_def.xml Edgar Link unprocessable
sprb-20230630_lab.xml Edgar Link unprocessable
sprb-20230630_pre.xml Edgar Link unprocessable
sprb-20230630_htm.xml Edgar Link completed